Alzheimer's Disease International

Adi hosted its conference in london, uk in june 2022. Over 1,200 delegates from over 120 countries participated including people living with dementia, caregivers, researchers, clinicians, as well as other staff and volunteers of alzheimer and dementia associations. It was the first time that it was offered in a hybrid format with both in-person and virtual sessions. The conference theme 'new horizons in dementia: building on hope', continued building upon the momentum of new knowledge, research and ideas, which ultimately intend to improve the lives of people living with dementia and their families.

World Alzheimer's month 2021 saw 111 countries participating, 45 million social media impressions of the hashtags and 461 pieces of traditional media coverage including bbc world service, nbc, wall street journal and astro awani. The world alzheimer report 2021, entitled 'journey through the diagnosis of dementia', includes over 50 essays from leading experts from around the world on the multifaceted issue of diagnosis and findings from global surveys which received responses from 1,111 clinicians, 2,325 people with dementia and carers, and 100 national alzheimer associations. Adi also launched the reports 'from plan to impact iv and contributed to other publications. Adi publishes a regular "global perspective" newsletter and other educational publications.

A three-day alzheimer university for emerging associations was held virtually in october 2021 with participants from 8 countries. A policy alzheimer university was held virtually in march 2022 with participants from 5 countries. 6 webinars for members were held with participants from 37 countries including media training, national dementia plans and catch-ups for exchange of ideas and experiences. Adi published online masterclasses on leadership and governance, and the association evaluation and development framework. Adi also offers one-to-one support and advice to associations.

In march 2022, the 4-year stride (strengthening responses to dementia in developing countries) project ended. Adi wrote a policy guide incorporating new methodology on vignettes, qualitative health economic data, and simulation and cost modelling. Adi conducted workshops on developing policy messaging and writing policy briefs. We worked to gather evidence to apply for anti-dementia drugs to be added to who's essential medicines list (eml). We collaborated in other research projects to promote the involvement of alzheimer associations particularly from low and middle income countries.